Mangoceuticals logo

MangoceuticalsNASDAQ: MGRX

Profile

Sector:

Healthcare

Country:

United States

IPO:

21 March 2023

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$5.93 M
-90%vs. 3y high
14%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
26%vs. sector
-99%vs. 3y high
67%vs. sector

Price

pre-market | Fri, 25 Oct 2024 09:28:58 GMT
$2.47+$0.16(+6.92%)

Dividend

No data over the past 3 years
$163.20 K-$2.39 M

Analysts recommendations

Institutional Ownership

MGRX Latest News

Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
newsfilecorp.com18 October 2024 Sentiment: POSITIVE

Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit, which will be taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 22nd to Wednesday, October 23rd, 2024, in Nassau, Bahamas. Jacob Cohen, Founder and CEO, is scheduled to present on Wednesday, October 23rd at 11:10 EDT.

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
globenewswire.com15 August 2024 Sentiment: POSITIVE

Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues.

Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
globenewswire.com18 July 2024 Sentiment: POSITIVE

DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that its CEO, Jacob Cohen, was recently featured on Benzinga All-Access.

MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department
globenewswire.com12 July 2024 Sentiment: POSITIVE

DALLAS, TEXAS, July 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that it has appointed Dr. Douglas Christianson, N.D. to serve as Director of the Medical Research and Product Innovation Department.

MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets
globenewswire.com11 July 2024 Sentiment: POSITIVE

DALLAS, TEXAS, July 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce that it has secured a strategic partnership with the International Society of Frontier Life Sciences and Technology (ISFLST) for the distribution of its products in China and the Asia Pacific region and Latin America (excluding Mexico). This agreement marks a significant milestone in MangoRx's expansion strategy, aiming to bring its premier men's health solutions to the rapidly growing markets in these regions.

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
globenewswire.com06 June 2024 Sentiment: POSITIVE

Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that it has received a Notice of Acceptance for Australian Patent Application No. 2020235666, which is the National Phase of International Application No. PCT/US2020/022903.

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
globenewswire.com04 June 2024 Sentiment: POSITIVE

Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that it has received a Notice of Allowance for Japanese Patent Application No. 2021-545824, originally applied for by Intramont Technologies, Inc. (“Intramont”).

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
globenewswire.com28 May 2024 Sentiment: POSITIVE

Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss and hormone replacement therapies, is pleased to announce that its subsidiary, MangoRx Mexico S.A. de C.V. (“MangoRx Mexico”), in conjunction with its Mexico-based pharmacy partner Emifarma S.A. de C.V (“Emifarma”), has successfully completed its first sample batch of Mango ED oral dissolvable tablets (ODTs) specifically to be marketed and sold in Mexico and other eligible Latin American (LATAM) countries.

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
globenewswire.com23 May 2024 Sentiment: POSITIVE

Dallas, TX, May 23, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, hormone replacement therapies and weight loss is excited to announce that it has engaged renown international performance marketing company, Crakmedia to champion the Company's ongoing creative and digital marketing initiatives.

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
globenewswire.com16 May 2024 Sentiment: POSITIVE

Mangoceuticals, Inc. (NASDAQ: MGRX) announced significant growth in revenue and customer acquisition in the first quarter of 2024 compared to the same period in 2023. The company reported a 108% increase in sales, reaching $214,000 USD, up from approximately $100,000 USD in the first quarter of 2023, indicating positive financial performance in Q1 2024.

What type of business is Mangoceuticals?

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

What sector is Mangoceuticals in?

Mangoceuticals is in the Healthcare sector

What industry is Mangoceuticals in?

Mangoceuticals is in the Health Information Services industry

What country is Mangoceuticals from?

Mangoceuticals is headquartered in United States

When did Mangoceuticals go public?

Mangoceuticals initial public offering (IPO) was on 21 March 2023

What is Mangoceuticals website?

https://www.mangoceuticals.com

Is Mangoceuticals in the S&P 500?

No, Mangoceuticals is not included in the S&P 500 index

Is Mangoceuticals in the NASDAQ 100?

No, Mangoceuticals is not included in the NASDAQ 100 index

Is Mangoceuticals in the Dow Jones?

No, Mangoceuticals is not included in the Dow Jones index

When was Mangoceuticals the previous earnings report?

No data

When does Mangoceuticals earnings report?

Next earnings report date is not announced yet